



















F Finetti et al. mPGES-1 mediates prostate
malignancy
22 :4 665–678mPGES-1 in prostate cancer controls
stemness and amplifies epidermal
growth factor receptor-driven
oncogenicityFederica Finetti1, Erika Terzuoli1, Antonio Giachetti1, Raffaella Santi2, Donata Villari3,
Hiromi Hanaka4, Olof Radmark4, Marina Ziche1,5 and Sandra Donnini1,5
1Department of Life Sciences, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
2Department of Surgery and Translational Medicine, University of Florence, Largo Brambilla 3, 50134 Firenze, Italy
3Department of Clinical and Experimental Medicine, University of Florence, Viale Pieraccini 18, 50139 Firenze, Italy
4Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden
5Istituto Toscano Tumori (ITT), Firenze, Italyhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0277
q 2015 The authors
Published by Bioscientifica Ltd
Printed in Great Britain
This work is l
Attribution 3Correspondence
should be addressed
to S Donnini or M Ziche
Emails
sandra.donnini@unisi.it or
marina.ziche@unisi.itAbstractThere is evidence that an inflammatory microenvironment is associated with the
development and progression of prostate cancer (PCa), although the determinants of intrinsic
inflammation in PCa cells are not completely understood. Here we investigated whether
expression of intrinsic microsomal PGE synthase-1 (mPGES-1) enhanced aggressiveness of PCa
cells and might be critical for epidermal growth factor receptor (EGFR)-mediated tumour
progression. In PCa, overexpression of EGFR promotes metastatic invasion and correlates with
a high Gleason score, while prostaglandin E2 (PGE2) has been reported to modulate oncogenic
EGFR-driven oncogenicity. Immunohistochemical studies revealed that mPGES-1 in human
prostate tissues is correlated with EGFR expression in advanced tumours. In DU145 and PC-3
cell lines expressing mPGES-1 (mPGES-1SC cells), we demonstrate that silencing or ‘knock
down’ of mPGES-1 (mPGES-1KD) or pharmacological inhibition by MF63 strongly attenuates
overall oncogenic drive. Indeed, mPGES-1SC cells express stem-cell-like features (high CD44,
b1-integrin, Nanog and Oct4 and low CD24 and a6-integrin) as well as mesenchymal transition
markers (high vimentin, high fibronectin, low E-cadherin). They also show increased capacity
to survive irrespective of anchorage condition, and overexpress EGFR compared to mPGES-1KD
cells. mPGES-1 expression correlates with increased in vivo tumour growth and metastasis.
Although EGFR inhibition reduces mPGES-1SC and mPGES-1KD cell xenograft tumour growth,
we show that mPGES-1/PGE2 signalling sensitizes tumour cells to EGFR inhibitors. We propose







(2015) 22, 665–678IntroductionProstate cancer (PCa) is currently treated with androgen
deprivation and chemotherapeutic agents. Resistance to
chemotherapy, a mounting issue in clinical oncology due
to its association with tumour recurrence, has hastenedthe search for new prognostic biomarkers and new
therapeutic targets aimed at patient stratification in
relation to treatment (Schrecengost & Knudsen 2013,
Augello et al. 2014). Because w40% of PCas expresssed under a Creative Commons
nported License.
Table 1 Gene expression of vimentin, fibronectin and ahnak
in DU145 cells expressing mPGES-1





















Research F Finetti et al. mPGES-1 mediates prostate
malignancy
22 :4 666epidermal growth factor receptor (EGFR), expression of
which is correlated with tumour recurrence and high
Gleason score, the receptor is assumed to be a potential
molecular target for advanced PCa. However, clinical trials
in PCa patients have shown limited efficacy of EGFR-
targeted drugs (Canil et al. 2005, Hammarsten et al. 2007,
Schlomm et al. 2007, Gravis et al. 2008, Nabhan et al.
2009). Multiple mechanisms, such as unrestrained
expression of EGFR, emergence of oncogenic mutants
(KRAS, BRAF and PIK3CA) and inactivation of the PTEN
tumour suppressor gene, underlie resistance to these
drugs. Acquired EGFR antagonist resistance is often
associated with the activation of bypass signalling path-
ways typically embedded in tumour cells or the surround-
ing tissue (Arteaga 2002, Wieduwilt & Moasser 2008,
Cathomas et al. 2012, Seshacharyulu et al. 2012).
Inflammatory molecules have been shown to enhance
EGFR oncogenic action in epithelial tumours, fostering
their propensity to metastasize. Many studies on the link
between inflammation and cancer have dealt with stimuli
originating from the cancer microenvironment
(extrinsic), providing strong support for this mechanism
(Mantovani et al. 2008, Hanahan & Weinberg 2011,
Coussens et al. 2013).
Microsomal PGE synthase-1 (mPGES-1), known to be
induced in inflammatory as well as tumour cells by pro-
inflammatory cytokines, such as interleukin-1 beta (IL-1b)
and tumour necrosis factor alpha (TNFa), contributes in a
critical way to tumour progression (Jakobsson et al. 1999,
van Rees et al. 2003, Takeda et al. 2004, Kamei et al. 2009,
Xu et al. 2012, Sha et al. 2013, Takahashi et al. 2014). We
recently found that EGFR activation up-regulates mPGES-1,
which in turn promotes phosphorylation of EGFR through
prostaglandin E2 (PGE2) (Donnini et al. 2012).
Here we investigated whether expression of intrinsic
mPGES-1 in advanced PCa cells enhanced their aggres-
siveness and might be critical for EGFR-mediated tumour
progression. To begin to understand the mechanism
underlying enhanced prostate oncogenic drive exerted
by mPGES-1, we first examined human PCa specimens
obtained after prostatectomy in a group of patients
showing various stages of malignancy. The close associ-
ation between mPGES-1 and EGFR expression observed in
these tumours led us to detailed study of this connection
in experiments on hormone-independent PCa cells
DU145 and PC-3 in vitro and in vivo. We demonstrate
that these cells have a mesenchymal phenotype and stem-
like features, which are likely to confer aggressive traits.
Evidence that intrinsic mPGES-1 underpins these traits is
seen in cell cultures in which ablation of the mPGES-1http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0277
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Printed in Great Britaingene (DU145 mPGES-1KD) or inhibition of mPGES-1
activity prevents development of a vigorous tumorigenic
phenotype. The enhanced oncogenic drive observed
in vitro translated to nude mice in vivo inoculated with
DU145 or PC-3 cells, as we found significantly higher
tumour growth and lung metastasis formation in mice
inoculated with PCa cells expressing mPGES-1. Further,
blockade of EGFR in vivo with erlotinib indicated the
possibility of quenching the oncogenic drive exerted by
malignant cooperation of the two signals (PGE2 and EGF).Materials and methods
Tumour samples
For PCa immunohistochemical study, formalin-fixed,
paraffin-embedded tissue blocks from 52 radical prosta-
tectomy specimens were retrieved from the archives of the
University of Florence (Florence, Italy). Informed consent
and approval according to the Helsinki Declaration were
obtained from the local ethics review board. The speci-
mens were reviewed by two genitourinary pathologists;
pathological stage and tumour grade were assigned
according to tumour/lympho-node/metastasis (TNM)
(2010) classification and the Gleason score, respectively
(Epstein et al. 2005, Edge et al. 2010). Twenty-five
carcinomas were limited to the prostate (pT2, organ-
confined PCa) and were moderately differentiated
(Gleason scoreZ6), whereas 27 cases (advanced PCa)
were non-organ-confined tumours (pT3/pT4) with a high
Gleason score (R7) (Table 1). The median age of patients
was 67.7 years (range 41–78 years).Immunohistochemical analysis of tumour samples
Tissue slides were deparaffinised in xylene and dehydrated
in ethanol. Microwave pre-treatment in EDTA (pH 9.0) (for
EGFR) or in citrate buffer (pH 6.0) (for mPGES-1 and a6-
integrin) was performed for 20 min. Endogenous peroxi-
dase activity was blocked with 3% hydrogen peroxide (v/v)
for 10 min and with 3% BSA (w/v) for 30 min. The slides
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22 :4 667a6-integrin (1:100; Santa Cruz, Heidelberg, Germany),
mPGES-1 (1:50; Thermo Scientific, Waltham, MA, USA)
and EGFR (1:100; Cell Signalling, Leiden, The Netherlands)
followed by chromogenic visualization using Immuno-
peroxidase Secondary Detection System kits (Chemicon,
Billerica, MA, USA). In particular, sections were incubated
for 15 min in the appropriate species-specific biotinylated
secondary antibodies and then with streptavidin-
conjugated HRP for 15 min. After incubation they were
exposed to 3,3-diaminobenzidine tetrahydrochloride
(Sigma) for 10 min to produce a brown reaction
product. After counterstaining with hematoxylin, slides
were washed thoroughly, dehydrated, cleared in xylene
and mounted. Staining intensity was scored as negative
(no staining) or positive (brown colour).Cell lines
DU145 WT (passages 5–20, ATCC HTB-81, certified by
STRA) is a PCa cell line with high constitutive expression
of mPGES-1 (Hanaka et al. 2009). DU145 mPGES-1
knockdown (mPGES-1KD cells, passages 8–20) and non-
target shRNA (mPGES-1SC cells, 8–20) cells were obtained
and cultured as described (Hanaka et al. 2009). PC-3 WT
(passages 8–20, ATCC CRL-1435, certified by STRA) and
LNCaP WT (passages 5–15, ATCC CRL-1740, certified by
STRA) PCa cells were from ATCC. Cells were grown in
RPMI (Euroclone, Pero Milano, Italy) and supplemented
with 10% FBS (v/v). Human umbilical vein endothelial
cells (HUVEC, passages 3–10) were from Lonza (Basel,
Switzerland) (C2519A, certified by expression of
CD31/105, vWFVIII, and positivity for acetylated low-
density lipoprotein uptake). Cells were grown in endo-
thelial growth medium (EGM-2) (Clonetics, Lonza) and
supplemented with 10% FBS (v/v).Transient mPGES-1 silencing
For siRNA transfection, the siRNAs sequence (human
mPGES-1: 50-CGGGCTAAGAATGCAGACTTT-30) was from
Qiagen. The day before transfection, cells were trypsinized
and 3!105 cells were seeded in six-well plates. Transient
transfection of siRNA was carried out using Lipofectamin
2000 (Invitrogen) according to the manufacturer’s
instructions. Cells were assayed 72 h after transfection.mPGES-1 shRNA transfection
Lenti vector plasmids for mPGES-1 knock down (Sigma)
and mPGES-1C/C (p Lenti vector with C-terminalhttp://erc.endocrinology-journals.org
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Printed in Great BritainMyc-DDK tag-NM_004878) were obtained from Sigma
and Origene (Origene, Rockville, MD, USA), respectively.
psPAX2 packaging plasmid (12260) and pMDG.2 envelope
plasmid (12259) were obtained from Addgene
(Cambridge, MA, USA).
All the plasmids were sequence-verified. To generate
mPGES-1 knock down (mPGES-1KD) cells or mPGES-1
overexpressing (C/C) cells, 1!106 HEK293 cells (Life
Technologies) were transfected with 2.25 mg of PAX2
packaging plasmid, 0.75 mg of PMD2G envelope plasmid
and 3 mg of pLKO.1 hairpin vector utilizing 12 ml of
Lipofectamine 2000 on 10 cm plates. Polyclonal popu-
lations of transduced cells were generated by infection
with 1 multiplicity of infectious units (MOI) of lentiviral
particles. Three days after infection, cells were selected
with 10 mg/ml puromycin (Gibco) or 20 mg/ml neomycin/
kanamycin (Sigma) for 1 week.Epithelial-mesenchymal transition PCR array
The expression of 88 human Epithelial-mesenchymal
transition (EMT) genes was profiled in DU145 cells using
the EMT-RT2 Profiler PCR Arrays (SAAB Bioscience,
Qiagen). Total RNA was isolated using an RNA Mini kit
(Qiagen) and reverse transcribed using an RT-PCR kit
(Qiagen). Relative expression was determined for each of
the 88 genes using the formula 2KDCt.Real-time PCR
Total RNA was obtained using an RNA Mini kit (Qiagen).
RNA (0.5 mg) was reverse transcribed using a RT-PCR kit
(Bio-Rad). Premixed primers for vimentin, fibronectin,
ahnak, ITGB1, Nanog, Oct4 and GAPDH (as internal
control) were from Applied Biosystems. Real-time PCR
was performed using SYBR Green Supermix (Bio-Rad)
according to the manufacturer’s instructions. RT-PCR was
performed using an iCycler iQ5 PCR Detection System.
The results are expressed as 2KDCt or fold increase.Western blot
Tumour cells (5!105) were seeded in 6 cm plates in
medium with 10% fetal bovine serum (FBS) (v/v) for 96 h,
then lysed and analysed. Where indicated, cells were
treated with PGE2 (1 mmol/l), erlotinib (10 mmol/l), NS398
(10 mmol/l) or [2-(6-chloro-1H-phenanthro-(9,10-d)
imidazol-2-yl)isophthalonitrile, MF63 (10 mmol/l). PGE2
and NS389 were from Sigma, erlotinib was from Santa Cruz
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22 :4 668translocation of b-catenin from cytosol to nucleus, cells
were trypsinized and homogenized on ice in lysis buffer
containing 0.1 mmol/l EGTA, 0.1 mmol/l EDTA,
10 mmol/l Hepes, 10 mmol/l KCl, protease and phospha-
tase inhibitors. After incubation on ice for 15 min,
Nonidet-P-40 was added to cell lysates, which were then
centrifuged (3900 g, 30 s). The supernatant contained the
cytosolic fraction, while the pellet was solubilized in lysis
buffer containing 1 mmol/l EGTA, 1 mmol/l EDTA,
20 mmol/l Hepes, 10 mmol/l NaCl, 1% protease and
phosphatase inhibitors (v/v), followed by incubation on
ice for 10 min and centrifuging (5480 g, 5 min). The
supernatant contained the nuclear fraction. An equal
amount of proteins was loaded on SDS–PAGE gel and
transferred to a nitrocellulose membrane. Western blot was
performed as described by Donnini et al. (2012). Sources of
antibodies were: anti-vimentin and anti-fibronectin, Sigma;
anti-anhak, Abcam (Cambridge, UK); anti-b-catenin, anti-
a6 integrin and anti-b1 integrin, Santa Cruz; anti-P-
Tyrosine, anti-EGFR, anti-caspase3 and anti-P-ERK1/2,
Cell Signalling; anti-PGE2 synthases, anti-COX synthases,
anti-PGDH, anti-PGT and anti-EP receptors, Cayman
Chemicals; anti-E-cadherin, DAKO (Milan, Italy). Images
were digitalized with CHEMI DOC Quantity One software,
blots were analysed in triplicate by densitometry using
NIH Image 1.60B5 Software, and arbitrary densitometric
units were normalized for b-actin (Sigma), tubulin (Santa
Cruz) or H2A (Abcam, UK).Tumour growth and lung metastasis in
immunodeficient mice
Experiments were performed according to Italian and EEC
guidelines for animal care and welfare (EEC Law No.
86/609). The experiments were approved by the Italian
Ministry of Health (215/2011-B). To assess the contri-
bution of mPGES-1 to the anti-tumour activity of
erlotinib, immunodeficient mice (5-week-old male athy-
mic mice, Harlan, Indianapolis, IN, USA) were inoculated
s.c. in the right flank with 20!106 DU145 cells (mPGES-
1SC or mPGES-1KD). When tumours reached a volume of
70–100 mm3, the animals were randomly assigned to
treatment with erlotinib (50 mg/kg, three times a week
by gavage). The first treatment is reported as day 1. Serial
calliper measurements of perpendicular diameters were
used to calculate tumour volume in mm3 with the
formula: shortest diameter!longest diameter!thickness
of tumour in millimeter. After treatment, animals were
sacrificed and tumours were collected and split in two
parts. One part was immediately frozen in liquidhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0277
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in Tissue-Tek O.C.T. (Sakura, Torrance, CA, USA) and
frozen in liquid nitrogen for histology (Donnini et al.
2007). For histology, see Supplementary Data, see section
on supplementary data given at the end of this article.
To assess the contribution of mPGES-1 to lung
metastases, DU145 and PC-3 PCa cells (mPGES-1SC or
mPGES-1KD) were suspended in PBS at a density of 20!106
cells/ml, and 250 ml of suspension was injected into the
tail vein. To investigate whether EGFR inhibition affected
the invasive activity of mPGES-1, cells were pre-treated
with erlotinib (10 mmol/l) for 72 h before injection. After
7 weeks, immunodeficient mice were sacrificed, lungs
removed and fixed in Bouin’s solution and the number of
metastatic colonies counted.MTT assay
Cell proliferation was quantified by Vybrant MTT cell
proliferation assay as described (Donnini et al. 2007). Briefly,
tumour cells (5!103) were seeded in 96-multiwell plates in
medium with 10% serum for 24 h and then, where indicated,
exposed to erlotinib (0.1–10 mmol/l) for 96 h in 10% FBS
(v/v). Results are reported as 540 nm absorbance/well.Adhesion
DU145 cells were maintained in 10% FBS (v/v) and then
trypsinized; 5!104 cells/ml in 1% FBS (v/v) medium were
seeded in 96 multiwell plates coated with human
fibronectin and incubated for 2 h at 37 8C. The wells
were washed gently with PBS and adherent cells were fixed
and stained with Diff-Quik. Adherent cells were counted
by microscope in five random fields at 200!.Tumour-endothelium adhesion
Tumour-endothelium adhesion was performed using the
CytoSelect tumour-endothelium adhesion assay kit
according to the manufacturer’s instructions (Cell Biolabs,
San Diego, CA, USA). Briefly, HUVEC cells (10!105
cells/well in 48 multiwell plates) were maintained in 10%
FBS (v/v) for 48 h. After monolayer formation, DU145 cells
were harvested and 1!106 cells/ml were suspended in
serum-free medium and incubated for 1 h in the presence
of CytoTracker. Cells were washed twice and added to the
endothelial cell monolayer. After 1 h cells were lysed and
the fluorescence read at 480 nm/520 nm. Where indicated,
endothelial cells were pre-treated for 4 h with TNFa to
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HUVEC cells (8!105 cells/well in the filter of a 48-well
transwell plate) were maintained in 10% FBS (v/v) for 48 h.
After monolayer formation, DU145 cells were harvested
and 1!106 cells/ml were suspended in serum-free medium
and incubated for 1 h in the presence of CytoTracker. Cells
were washed twice with serum-free medium and 2!105
cells were added to the upper side of the transwell plate.
After 2 h the medium in the lower side of the plate was
collected and centrifuged. Migrant tumour cells were lysed
and fluorescence measured at 480 nm/520 nm.Cell viability assay
Tumour cells at a density of 5!105 cells/ml were
incubated for 24 or 48 h in medium with 0.1% FBS (v/v).
After incubation, the numbers of dead cells stained with
trypan blue and total cells were evaluated by optical
microscope. The number of dead cells was reported as a
percentage of total cells.Flow cytometry
Tumour cells were harvested and 3.5!104 cells were
incubated in ice for 30 min with primary antibody, then
washed in PBS and exposed to secondary antibody for an
additional 30 min. Surface CD44 and CD24 (Abcam) were
quantified by flow cytometry using unlabelled monoclonal
or polyclonal Ab followed by fluorescein isothiocyanate
(FITC) or tetramethylrhodamine (TRIC)-labelled second-
ary antibodies. Cells were analysed by flow cytometry using
a FACScan flow cytometer (Becton-Dickinson, Franklin
Lakes, NJ, USA). Data was acquired by CellQuest and
plotted using FlowJo (Tree Star, Ashland, OR, USA).Clonogenic assay
Tumour cells were plated in 60 mm culture dishes (1000
cells per dish) in medium containing 10% FBS. After 24 h
cells were treated with erlotinib or MF63 (1–10 mmol/l) in
10% FBS (v/v) and kept in a humidified incubator for
10 days. Colonies (O50 cells) were fixed and stained with
0.05% crystal violet (w/v) (Sigma) in 10% ethanol (v/v),
counted and photographed.Statistical analysis
Results were expressed as meansGS.E.M., analysed by
Student’s t-test and/or one-way ANOVA with Bonferroni’shttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0277
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statistical significance.Results
mPGES-1 promotes the mesenchymal and stem cell-like
phenotype in PCa cells
We investigated the correlation of mPGES-1 expression
(immunohistochemistry) with staging and grading in a
series of PCa cases. Overall, mPGES-1 expression was
detected in 12/25 (48%) organ-confined PCa and in 21/27
(77.7%) advanced PCa (Fig. 1A). In human advanced PCa
samples, both mPGES-1 and EGFR were co-expressed in a
high percentage of cases (nZ19/27, 70.3%; Fig. 1A). In the
same group, a6-integrin, a stem cell marker (Marthick &
Dickinson 2012, Hoogland et al. 2014), was negative or
weakly stained (nZ19/27; Fig. 1B). By contrast, only 7/25
(28%) of organ-confined tumours showed co-expression of
mPGES-1 and EGFR (Fig. 1A, 70.3% vs 28%, see also panel
a and b from an organ confined PCa sample vs c and d
from an advanced PCa sample).
In DU145 cell line isolated from a castration-resistant
human brain metastasis of PCa, characterized by mPGES-1
expression (mPGES-1SC) (Hanaka et al. 2009), the knock
down for mPGES-1 (stable or transient mPGES-1KD) did
not affect PGE2 receptor expression (EP1-4), while it
obliterated PGE2 output (O90%, P!0.001 vs mPGES-1
SC)
(A and B, and Supplementary Figure 1, see section on
supplementary data given at the end of this article). The
large PGE2 loss occurred despite a slight increase in
cyclooxygenase-2 (COX-2) expression, while other
enzymes involved in PGE2 metabolism were either
unchanged (e.g. COX-1), or only negligibly changed (e.g.
the cytosolic isoform, cPGES, the microsomal type 2
isoform, mPGES-2, the prostaglandin transporter, PGT
and the enzyme implicated in PGE2 degradation,
15-hydroxyprostaglandin dehydrogenase (PGDH))
(Fig. 2A). Compared to DU145 WT, transfection of cells
with the empty vector (mPGES-1SC) did not affect the PGE2
signalling cascade (Fig. 2A). Similar results were obtained
in experiments of transiently silenced mPGES-1 cells
(Supplementary Figure 2A).
Because PGE2 regulates genes involved in EMT in
tumour cell lines (Dohadwala et al. 2006), we assessed
whether constitutively high mPGES-1 expression in
DU145 affected their mesenchymal-cell-like phenotype
with respect to mPGES-1KD cells. The results showed that
w1/4 of EMT-related genes (nZ22/88) were influenced by
high expression of intrinsic mPGES-1 (Fig. 2B). NotablePublished by Bioscientifica Ltd.
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Immunohistochemical expression of mPGES-1, EGFR and a6-integrin in
prostate cancer. (A) Representative images of mPGES-1 and EGFR
expression in organ-confined (a and b) or advanced (c and d) prostate
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22 :4 670changes occurred in transcription factors known to induce
EMT, such as Snail, Slug (SNAI2 gene) and ZEB, and in
several genes coding for cytoskeletal proteins, such as
E-cadherin, vimentin, fibronectin and ahnak. Western
blot and immunofluorescence analysis illustrated the
marked loss of vimentin, fibronectin and ahnak and the
increased expression of E-cadherin in stably and transi-
ently silenced mPGES-1KD cells (C and D). Reduced
expression of vimentin, fibronectin and ahnak was also
detected by quantitative RT-PCR (Table 1). Treatment of
mPGES-1KD cells with PGE2 (1 mmol/l, 24 h) reversed both
vimentin and fibronectin expression, confirming the
involvement of PGE2 in this process (Fig. 2E). In line
with the role of PGE2 in cancer cell growth and E-cadherin
expression (Castellone et al. 2005, Lu et al. 2012), we found
massive translocation of b-catenin into the nucleus ofhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0277
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Printed in Great BritainDU145 mPGES-1SC cells, while it remained localized in the
cytoplasm of mPGES-1KD cells (Fig. 2E and F).
We also observed a prevalence of stem-cell-like
markers, regarded as indicators of tumour invasiveness, in
DU145 mPGES-1SC compared to mPGES-1KD cells. This was
indicated by the large increase in the CD44C/CD24K ratio,
the decrease in a6-integrin and the increase in b1
integrin, as well as transcription factors Nanog and Oct4
in mPGES-1SC (Fig. 3A, B and C), all pluripotency
maintaining factors overexpressed in PCa stem cells
(Klarmann et al. 2009, Rentala et al. 2010, Marthick &
Dickinson 2012, Nanta et al. 2013, Hoogland et al.
2014).Similar results were obtained for the PC-3 cell line.
PC-3 cells expressed constitutive mPGES-1, and knocking
down the enzyme significantlyreduced PGE2 output







































































mPGES-1 promotes EMT in DU145 cells. (A) Expression of enzymes involved
in arachidonic acid cascade in DU145 WT, mPGES-1SC and mPGES-1KD cell
lines in basal condition (10% FCS) measured by western blot. (B) EIA
analysis of PGE2 production measured in medium conditioned by DU145
cells. Results (three experiments run in duplicate) are expressed as pg/ml of
PGE2. ***P!0.001 vs mPGES-1
SC-. (C and D) Representative images and
quantification of western blot analysis of E-cadherin, vimentin, fibronectin
and ahnak expression in DU145 cells. *P!0.05, **P!0.01 and ***P!0.001
vs DU145 mPGES-1SC (E) Western blot analysis of fibronectin and vimentin
in mPGES-1KD cells treated with PGE2 (1 mmol/l, 24 h). (F) Western blot
analysis of b-catenin localization in DU145 mPGES-1SC and mPGES-1KD cells.
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expression of stem cell markers (Supplementary Figure 3A,
B, C, D, E and F, see section on supplementary data given at
the end of this article). We also recorded anchorage-
independent cell viability in mPGES-1SC cells, in contrast
to the drastic decline seen in mPGES-1KD cells, associated
with caspase-3 activation (Fig. 3D and E, and Supplemen-
tary Figure 3G and H). Adhesion studies with fibronectin
coated-wells or endothelial cells revealed that mPGES-1SC
cells rapidly adhered (2 h) to the matrix or endothelium
(whether or not it had been activated by TNFa to favour
cell–cell interaction and transmigration), whereas mPGES-
1KD cells displayed a significantly delayed adhesion (F and
G). Since knock down of mPGES-1 in cells does not affect
cell survival in vitro, as measured by MTT assay (Abs 0.95G
0.08 and 0.88G0.11 for DU145 mPGES-1SC and mPGES-1KDhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0277
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Printed in Great Britaincells; Abs 0.74G0.06 and 0.79G0.09 for PC-3 mPGES-1SC
and mPGES-1KD cells respectively), or cell apoptosis in
suspension up to 24–48 h, we conclude that the inhibition
of adhesion in mPGES-1KD cells depends on the modi-
fication of cytoskeletal organization, for example of
vimentin and fibronectin. Finally, by measuring trans-
endothelial migration, we showed a far greater ability
(nearly threefold) of mPGES-1SC than mPGES-1KD cells to
cross cell layers (Fig. 3H), indicating the involvement of
mPGES-1/PGE2 signalling in prostate tumour invasiveness.Inhibition of mPGES-1 activity suppresses stem-like
phenotype
Further evidence that the mPGES-1-PGE2 cascade











































































































































































































EGFR activation mediates mPGES-1/PGE2-dependent EMT of DU145 cells.
(A) FACS analysis for CD24 and CD44 expression in DU145 mPGES-1SC-and
mPGES-1KD cells, and (B) western blot analysis and quantification of a6 and
b1-integrin expression in mPGES-1SC and mPGES-1KD cells. Data are
representative of three different experiments and quantification was
performed by Image J. *P!0.01 vs DU145 mPGES-1SC (C) RT-PCR analysis of
Nanog and Oct4 expression in mPGES-1SC and mPGES-1KD DU145 cells.
Data are reported as fold increase vs mPGES-1SC cells. **P!0.01 vs DU145
mPGES-1SC. (D) Cell viability of DU145 mPGES-1SC and mPGES-1KD in
suspension in 0.1% of serum. Results are expressed as % of dead cells.
**P!0.01 and ***P!0.001 vs DU145 mPGES-1SC. (E) Western blot analysis
of caspase 3 activation in DU145 cells grown in suspension for the indicated
time. (F) Adhesion of DU145 mPGES-1SC and mPGES-1KD untreated or
pretreated with PGE2 (1 mmol/l, 96 h) on fibronectin coated-96 well plate.
Cell adhesion was evaluated after 2 h of incubation in 1% serum. Results
(three experiments in triplicate) are expressed as % of adherent cells
relative to untreated mPGES-1SC. **P!0.01 vs mPGES-1SC; ###P!0.01 vs
mPGES-1KD. (G) CytoTracker labeled DU145 mPGES-1SCor mPGES-1KD cells
were allowed to attach to untreated or TNFa-pre-treated HUVEC
monolayers in 48 well plates for 1 h. Adherent cells were lysed and
quantified. Results (three experiments in duplicate) are expressed as fold
increase to the adhesion of mPGES-1SC on untreated HUVEC. **P!0.01 vs
mPGES-1SC. (H) Migration of DU145 mPGES-1SC and mPGES-1KD toward
HUVEC monolayer. CytoTracker labeled tumor cells were seeded in the
upper side of 48 well-transwell and migration was evaluated after 2 h by
measuring the fluorescence in the lower side of the well. Data are reported
as relative fluorescence unit of three experiments run in duplicate.
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MF63 (Xu et al. 2008). MF63 (10 mmol/l, 24–48 h)
significantly inhibited PGE2 production and reversed the
mesenchymal phenotype in DU145 and PC-3 cells,
promoting E-cadherin and inhibiting vimentin expression
(Fig. 4A, B and C). MF63 also upregulated a6-integrin and
significantly reduced cell clonogenicity (Fig. 4D and E).
To complement the above findings, we also trans-
fected mPGES-1 in LNCaP PCa cells, isolated from a
castration-resistant human lymph node metastases lack-
ing constitutive mPGES-1 (Supplementary Figure 4A, see
section on supplementary data given at the end of this
article). As expected, forced expression of mPGES-1 in
LNCaP cells promoted an increase in PGE2 production, cell
growth and development of the mesenchymal phenotype
as documented by E-cadherin decrease (Supplementary
Figure 4B, C, D and E).mPGES-1 induces growth and lung metastasis formation
In light of the observed link between mPGES-1/PGE2
signalling, EMT and stemness markers in PCa cells, wehttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0277
q 2015 The authors
Printed in Great Britaininvestigated whether the presence of mPGES-1 in DU145
and PC-3 cells influenced their growth and metastatic
invasion in vivo.
In tumours induced by inoculating nude mice with
mPGES-1SC or mPGES-1KD cells, the volume measurements
(here reported at days 12 and 21) showed significant
differences, growth being 2.3-fold higher in DU145
mPGES-1SC than mPGES-1KD tumours, and 4.9-fold higher
in PC-3 mPGES-1SC than mPGES-1KD tumours (Fig. 5A).
Consistently, Ki-67 showed denser immunostaining in
mPGES-1SC than mPGES-1KD tumours (Fig. 5B). Accordingly,
the Ki67 score was 45G2.9% and 57G3.8% for DU145 and
PC-3 mPGES-1SC respectively and 21G1.9% and 29G1.8%
for DU145 and PC-3 mPGES-1KD respectively, indicating a
higher proliferation rate in cells overexpressing mPGES-1.
Western blot (Fig. 5C) and immunohistochemistry of
tumours (Fig. 5D) revealed abundant mPGES-1 and
vimentin expression in mPGES-1SC, contrasting with the
absence of these two proteins in mPGES-1KD tumours.
We also investigated the contribution of mPGES-1
expression to PCa metastasis by injecting DU145 and PC-3
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Pharmacological inhibition of mPGES-1 controls EMT markers, a6-integrin
and EGFR expression, and reduces prostate cancer cells growth. (A). EIA
analysis of PGE2 production measured in medium conditioned by DU145 or
PC-3 cells after 48 h of treatment with MF63 (10 mmol/l). Results (three
experiments run in duplicate) are expressed as pg/ml of PGE2. **P!0.01 vs
basal. (B, C and D) Western blot analysis of E-cadherin, vimentin and
a6-integrin expression after MF63 treatment (10 mmol/l). (E). Quantification
of DU145 and PC-3 colonies in the presence or absence of MF-63 10 mmol/l.
Data are reported as the number of colonies of three experiments in
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or PC-3 mPGES-1SC, the number of lung colonies was
18G2 and 20G3.8, respectively. In contrast, knock down
of mPGES-1 significantly reduced the numbers of colonies
(10G1.9 and 3.3G2.8 respectively, Fig. 5E).
These results demonstrate that mPGES-1/PGE2 signal-
ling plays a significant role in prostate tumour growth and
metastasis development.mPGES-1 induces EGFR expression in prostate tumours
and mediates EGFR-dependent tumour growth
It is well documented that PGE2 favours EGF/EGFR-induced
oncogenicity by directly phosphorylating EGFR (Buchanan
et al. 2003, Donnini et al. 2007). However, it is unknown
whether mPGES-1/PGE2 signalling modulates EGFR
expression levels.We measured EGFR expression in DU145
mPGES-1SC and mPGES-1KD cells, in tumours from mice
inoculated with the respective cell lines and in DU145 and
PC-3 treated with MF63. We found distinctly higher EGFR
expression levels in themPGES-1SC groupthaninthemPGES-
1KD group (A, B and C and Supplementary Figure 2B).
Consistently, p-ERK1/2, a known downstream effector of
EGFR signalling, was higher in mPGES-1SC than mPGES-1KD
tumours (Fig. 6D), suggesting that EGFR signalling plays a
role in mPGES-1 enhancement of tumour growth.
Moreover, treatment of DU145 and PC-3 mPGES-1SC
cells with mPGES-1 inhibitor MF63 (10 mmol/l) and
DU145 mPGES1SC cells with COX-2 inhibitor NS398
(10 mmol/l, 96 h) inhibited EGFR expression (Fig. 6E and
F), while exogenous PGE2 (1 mmol/l, 96 h) increased EGFRhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0277
q 2015 The authors
Printed in Great Britainprotein levels in DU145 mPGES-1KD cells, supporting
involvement of PGE2 in promoting EGFR over-expression
in prostate tumours.
Further evidence of involvement of mPGES-1/PGE2
signalling in EGFR expression was obtained in exper-
iments in vitro and in vivo using erlotinib, a known
inhibitor of EGFR. In vitro, erlotinib administration to
DU145 cells (10 mmol/l) abrogated EGFR phosphorylation
and downregulated vimentin expression (Fig. 6G). Phos-
phorylation of EGFR was independent of EGF expression,
which was affected in mPGES-1KD cells but not in mPGES-
1SC (Supplementary Figure 5, see section on supplemen-
tary data given at the end of this article). Erlotinib also
reduced cell viability in DU145 mPGES-1KD cells and
functionally halved the number of cell colonies (number
of colonies: mPGES-1SCZ58G4 vs mPGES-1KDZ27G5)
(Fig. 6H, I, J, K and L). In vivo, erlotinib decreased tumour
growth in DU145 mPGES-1SC and mPGES-1KD-bearing
mice with respect to the vehicle-treated group (area under
curve: mPGES-1SCCerlotinibZ12360 vs mPGES-1KDC
erlotinibZ5664, Fig. 6M). Erlotinib treatment was more
effective in reducing tumour volume when mPGES-1 was
knocked down (Fig. 6I), but it did not affect the number of
metastases for DU145 and PC-3 cell lines (number of
metastases: mPGES-1SCZ20G4.8 and mPGES-1KDZ7.5G
3.5 for DU145; mPGES-1SCZ17. 7G4.2 and mPGES-1KDZ
5.3G3.4 for PC-3).
All together, this data provides clear evidence of the
role played by the mPGES-1/PGE2 pathway in inducing a
mesenchymal phenotype and stemness in PCa cells, thus





























































































mPGES-1 expression controls in vivo tumor growth, vimentin and EGFR
expression. (A). Tumor volume measured in athymic mice inoculated with
DU145 and PC-3 mPGES-1SC or mPGES-1KD cells after 12 or 21 days. *P!0.05
and **P!0.01 vs mPGES-1SC. (B) Immunohistochemical analysis of Ki67
expression in tumor specimens derived from mPGES-1SCor mPGES-1KD. Data
are representative of five tumor specimens for both tumor cell types.
(C and D) Western blot and immunohistochemical analysis of vimentin
expression in xenograft tumor tissues. Data are representative offive tumor
specimens for both tumor cell types. (E). Quantification and images of lung
metastasis after injection in mice tail vein of DU145 or PC-3 mPGES-1SC or
mPGES-1KD cells. Images: grey frame: DU145; black frame: PC-3. *P!0.05
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The present study shows that by eliciting mesenchymal
and stem-cell-like traits and EGFR expression, the tumour
intrinsic inflammatory mPGES-1/PGE2 pathway
cooperates with the EGFR oncogene to promote an
aggressive PCa phenotype.
As an experimental paradigm we used DU145 and
PC-3 cells in which mPGES-1 was stably or transiently
knocked down by mRNA silencing (mPGES-1KD), compar-
ing them with prostate cells containing a negative control
non-targeting shRNA plasmid (mPGES-1SC). Further,
evidence of the specificity of mPGES-1/PGE2 signalling in
PCa aggressiveness was obtained by pharmacological
inhibition of the enzyme with the selective MF63
inhibitor (Xu et al. 2008).http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0277
q 2015 The authors
Printed in Great BritainInflammation plays a role in the development and
progression of many cancers, including PCa, and multiple
pro-inflammatory molecules are associated with PCa
recurrence (Ørsted & Bojesen 2013). Here we investigated
the contribution of the mPGES-1/PGE2 pathway to EMT, a
process that promotes acquisition of mesenchymal traits,
such as enhanced growth and migratory capacity, inva-
siveness and resistance to apoptosis, by epithelial cells. We
observed that mPGES-1 knockdown influenced a set of
genes promoting EMT in tumour cells, such as genes
coding for transcriptional activity (Snail, Slug and ZEB),
which were significantly downregulated. The effect on the
cytoskeletal protein vimentin, which became undetect-
able in mPGES-1KD and in cells treated with MF63, was
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mPGES-1 expression in cells mediates prostate tumor responsiveness to
erlotinib. (A) Western blot analysis of the EGFR expression in DU145
mPGES-1SC and mPGES-1KD cells in basal condition or treated for 96 h with
1 mmol/l PGE2. Graph: quantification of EGFR expression. Data (three
experiments) represent the ratio between EGFR and actin. **P!0.01 vs
mPGES1SC and ##P!0.01 vs mPGES-1KD. (B) Immunofluorescence analysis of
EGFR expression in mPGES-1SC and mPGES-1KD cells. (C and D) EGFR
expression and ERK 1/2 phosphorylation in tumor specimens derived from
DU145 mPGES-1SC and mPGES-1KD. (E and F) Western blot analysis of EGFR
expression in DU145 and PC-3 mPGES-1SC treated with MF63 (10 mmol/l,
24–72 h), in DU145 mPGES-1SC treated with NS398 (10 mmol/l, 96 h) and in
DU145 mPGES-1KD treated with PGE2 (1 mmol/l, 96 h). Representative gels
of three experiments. (G) Western blot analysis of EGFR phosphorylation
and vimentin expression in DU145 mPGES-1SC cells treated with erlotinib
(10 mmol/l, 96 h). Data are representative of three experiments. (H) MTT
assay of DU145 mPGES-1SC and mPGES-1KD cells treated with erlotinib
(0.01–10 mmol/l, 96 h). Data (three experiments in triplicate) are reported as
cell death (%). (I) Representative colonies of DU145 mPGES-1SC and mPGES-
1KD cells. (J) Quantification of DU145 mPGES-1SC and mPGES-1KD colonies in
the presence or absence of erlotinib 1 and 10 mmol/l. Data are reported as D
of mPGES-1SC and mPGES-1KD cell colonies in the presence of erlotinib over
the control (%) and are the means of three experiments in duplicate.
*P!0.05 vs mPGES-1SC; **P!0.01 vs mPGES-1KD. (K) Tumor volume
measured in athymic mice inoculated with DU145 mPGES-1SC or mPGES-1KD
cells and treated with erlotinib (400 mg/mouse per three times per week,


















Research F Finetti et al. mPGES-1 mediates prostate
malignancy
22 :4 675in mPGES-1KD cells. They included downregulation of
insulin growth factor binding protein-4 (IGFBP-4) and the
integrin b1 (ITGB1) gene, re-localization of b-catenin and
overexpression of E-cadherin. All these markers are known
to be associated with PCa aggressiveness (Damon et al.
1998, Miyake et al. 2000, Mohan & Baylink 2002,
Bijnsdorp et al. 2013, Carbonell et al. 2013).
Regulation of these markers may therefore be causallyhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0277
q 2015 The authors
Printed in Great Britainrelated to the loss of function parameters observed in
mPGES-1KD cells.
mPGES-1 expression in PCa cells was clearly associated
with stem-like features as demonstrated by the greater
survival ability of mPGES-1SC cells in suspension
compared to mPGES-1KD cells. Additional evidence of
mPGES-1-linked stemness was a significant shift in
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Nanog and Oct4 (Nanta et al. 2013). Collectively, these
results provide evidence of involvement of mPGES-1/PGE2
in promoting EMT and stemness in mPGES-1SC tumour
cells, since its ablation and inhibition impairs their
inherent potential to survive in suspension and to
transmigrate to endothelial cells.
EGFR studies provided another means to examine the
interplay between PGE2 input and oncogenic drive
mediated by the EGFR system. The picture emerging is
one of reciprocal activation producing vigorous PCa
progression when both components (PGE2 and EGF) of
this circuit are maximally expressed, as in mPGES-1SC
cells, and conversely, a reduced outcome in mPGES-1KD
and in mPGES-1-inhibited cells, in which both com-
ponents are downregulated. This circuit appears to be
operant in the clinical setting here reported, as in human
prostate tumours mPGES-1 and EGFR are concomitantly
expressed in specimens with a high Gleason score
compared to specimens of organ-confined lesions with
a low Gleason score. Thus, mPGES-1/PGE2 signalling
empowers tumour cells to disseminate and seed meta-
stases by activating EMT and stemness in PCa.
The present findings illustrate the role of mPGES-1
signalling in influencing EGFR-mediated oncogenicity
and in contributing, in association with the EGFR path-
way, to aggressiveness in PCa. Indeed, erlotinib treatment
reduced tumour development in the mPGES-1SC group to
approximately the same level as that observed in mPGES-
1KD tumours. Further, ablation of PGE2 production
significantly reduced lung metastasis in mice, indicating
that mPGES-1 signalling plays a key role in EMT and
stemness of PCa cells (Oskarsson et al. 2014). The
combination of mPGES-1 knockdown or pharmacological
inhibition of mPGES-1 by MF63 with erlotinib results in a
more effective strategy to inhibit PCa cell growth. Ability
to undergo EMT and acquire stem-cell-like features
enables tumours to expand, spread and resist chemother-
apy/target therapy (Clevers 2011, Hoggatt et al. 2013).
PGE2 release in the tumour microenvironment was
recently shown to be responsible for tumour initiation
and repopulation, hence inhibitors of PGE2 production
interfere with tumour progression and chemoresistance
(Kurtova et al. 2015). Our study demonstrates that
mPGES-1 ablation or inhibition in human PCa cells
suppresses their overall oncogenic drive and reduces
their stemness and invasiveness. We conclude that the
mPGES-1 gene may be considered a signature gene for
identifying a subtype of rapidly progressing prostate
tumours, which, in the case of overexpression of EGFR,http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0277
q 2015 The authors
Printed in Great Britainmay benefit from combined treatment with inhibitors of
EGFR, tyrosine kinase and PGE2.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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Ristimäki A 2003 Expression of microsomal prostaglandin E synthase-1
in intestinal type gastric adenocarcinoma and in gastric cancer cell
lines. International Journal of Cancer 107 551–556. (doi:10.1002/ijc.
11422)
Rentala S, Yalavarthy PD & Mangamoori LN 2010 a1 and b1 integrins
enhance the homing and differentiation of cultured prostate cancer
stem cells. Asian Journal of Andrology 12 548–555. (doi:10.1038/aja.
2010.20)
Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, Chun FH,
Haese A, Kollermann J, Graefen M et al. 2007 Clinical significance of
epidermal growth factor receptor protein overexpression and gene copy
number gains in prostate cancer. Clinical Cancer Research 13 6579–6584.
(doi:10.1158/1078-0432.CCR-07-1257)
Schrecengost R & Knudsen KE 2013 Molecular pathogenesis and
progression of prostate cancer. Seminars in Oncology 40 244–258.
(doi:10.1053/j.seminoncol.2013.04.001)
Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK & Batra SK
2012 Targeting the EGFR signaling pathway in cancer therapy. Expert
Opinion on Therapeutic Targets 16 15–31. (doi:10.1517/14728222.2011.


















Research F Finetti et al. mPGES-1 mediates prostate
malignancy
22 :4 678Sha W, Olesch C, Hanaka H, Rådmark O, Weigert A & Brüne B 2013
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